A Phase 1/2, Drug-Drug Interaction Study of FDL169 and FDL176 in Healthy Subjects and in Cystic Fibrosis Subjects Homozygous for the F508del-CFTR Mutation
Phase of Trial: Phase I/II
Latest Information Update: 02 Aug 2019
Price : $35 *
At a glance
- Drugs FDL 169 (Primary) ; FDL 176 (Primary)
- Indications Cystic fibrosis
- Focus Pharmacokinetics
- Sponsors Flatley Discovery Lab
- 30 Jul 2019 Protocol has been amended due to change in treatment arms from two to four, phase from I to phase I/II and design keywords from open label to double blind.
- 30 Jul 2019 Planned number of patients changed from 32 to 78.
- 30 Jul 2019 Planned End Date changed from 1 Mar 2019 to 1 Feb 2020.